Search Results
483 results found for "Cost-efficient medications https://simplemedrx.top"
- Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Agreement with the Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS
About Alzheimer’s Disease and Other Disorders of Cognitive Impairment Today there is significant unmet medical Healthcare costs associated with the epidemic of Alzheimer’s, including nursing home care, continue to projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Clinical Design Expert to Scientific Advisory Board
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Alzheimer's Industry Leader to Scientific Advisory Board
Gold served as the Chief Medical Officer of Allon Therapeutics, where he led a large pan-US and European projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex CEO to Participate in Brean Capital 2013 Life Sciences Summit
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Announces Expansion of Scientific Advisory Board
He is Associate Professor of Pathology and Cell Biology at the Columbia University Medical Center and Fellowship” (Georgetown University), the “Anna Villa Rusconi Foundation Prize” (Italy), the “INSERM Poste projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Reports Predicted Clinical Effect for ANAVEX 2-73 in Computer Simulation Model of AD
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Announces Positive Data for ANAVEX 2-73 in Alzheimer's Disease
The compound may enable effective brain protection during the most aggressive phase of the disease pathology The full poster is available on the Anavex website at https://anavex.com//publications.html. projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex CEO to Present Clinical Prediction Data for ANAVEX 2-73 at CNS Summit 2013
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Reports ANAVEX 2-73 Blocks Tau and Amyloid-Beta Proteins in a Preclinical Model of AD
This compares to most other current AD clinical development compounds that are mainly downstream and Both can efficiently alleviate these two major alterations observed in the Alzheimer’s animal model, Missling, PhD, President and Chief Executive Officer of Anavex, said, “Using further upstream targets that efficiently The full paper is available on the Anavex website at https://anavex.com//publications.html. Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex to Present Data for ANAVEX 2-73 at Society for Neuroscience 2013 Annual Meeting
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
